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Abstract
Background: The spread of multidrug-resistant tuberculosis (MDR-TB) strains has become a challenge to the global
TB control and prevention program. In Ethiopia, particularly in rural areas, information on drug-resistant TB is very
limited. In this study, we determined the drug resistance patterns of Mycobacterium tuberculosis (M. tuberculosis)
isolates from pulmonary TB patients attending two public hospitals in the East Gojjam zone of northwest Ethiopia.
Methods: A cross-sectional study was conducted between May 2011 and January 2012 using Region of difference-9
(RD9) typing for the identification of species mycobacterium. Drug susceptibility testing (DST) of M. tuberculosis isolates
to the first-line drugs: isoniazid, rifampicin, ethambutol and streptomycin was performed by the indirect proportion
method on Middle brook 7H10 Agar media.
Results: Out of 385 pulmonary TB suspects studied, 124 (32.2 %) were culture positive among which 120 were M.
tuberculosis strains. Susceptibility testing was performed for 89 isolates. Resistance to at least one drug was 15.58 %
([12/77], 95 % CI: 7.48-23.68) among newly diagnosed and 50.0 % ([6/12], 95 % CI: 21.71-78.29) among previously
treated cases. Resistance among newly diagnosed patients was most common for streptomycin 5.19 % (4/77) and
ethambutol 5.19 % (4/77) followed by rifampicin 3.89 % (3/77). Among retreatment cases, isoniazid resistance was most
frequent in which 33.33 % (4/12) of the isolates were resistant. MDR prevalence was 1.29 % (1/77) for newly diagnosed
and 16.67 % (2/12) for retreatment cases. In a multivariate logistic regression analysis, age group of 25–34 years
(adjusted OR = 4.24; 95 % CI: 1.02-17.5; P = 0.046) and previous history of treatment (adjusted OR = 5.42; 95 % CI:
1.56-27.49; P = 0.01) were independently associated with anti-TB drug resistance.
Conclusions: In general, the magnitude of anti-TB drug resistance including MDR-TB was comparable to previous
studies in other areas of Ethiopia. However, rifampicin resistance was high, which could suggest the potential for
a rise in the incidence of MDR. Therefore, re-enforcing TB control programs should be considered by the
concerned public health authorities.
Keywords: Mycobacterium tuberculosis, Drug resistance, MDR-TB, Ethiopia
* Correspondence: ingoldmlt@gmail.com
1Institute of Biomedical Sciences, College of Health Sciences, Mekelle
University, PO Box 1872, Mekelle, Ethiopia
2Aklilu Lemma Institute of Pathobiology, Addis Ababa University, PO Box
1176, Addis Ababa, Ethiopia
Full list of author information is available at the end of the article
© 2015 Adane et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Adane et al. BMC Public Health  (2015) 15:572 
DOI 10.1186/s12889-015-1933-9
Background
The emergence of drug-resistant tuberculosis is a critical
threat to tuberculosis (TB) control and is a major public
health concern in several countries. Multidrug-resistant
TB (MDR-TB), defined as resistant to at least isoniazid
and rifampicin, is emerging as a major clinical and pub-
lic health challenge in areas of sub-Saharan Africa [1].
Ethiopia is one of the high TB and HIV burdened coun-
tries in sub-Saharan Africa which ranks 7th among the
22 high TB burden countries in the world [1]. According
to the WHO 2013 report, the prevalence and incidence
rates of TB in the country were 224/100,000 and 247/
100,000 populations, respectively. The rate of MDR-TB
was estimated to be 1.6 % and 12 % of new and retreat-
ment cases, respectively [1].
In countries with high burden of TB, continuous sur-
veillance and regular monitoring of drug resistance
based on routine drug susceptibility testing (DST) of TB
patients is essential to assess the magnitude and trends
of anti-TB drug resistance [1, 2]. However, in Ethiopia,
there is limited capacity to perform culture and DST of
M. tuberculosis, even from patients suspected of har-
bouring drug-resistant strains. As a consequence, many
of MDR-TB patients remain undiagnosed which nega-
tively impacts the global strategy of halting and eliminat-
ing TB [3].
Few studies previously conducted in Ethiopia indicated
drug resistance proportions ranging from 14.6 %-30.1 %
[4–6] and 11.1 %-42.1 % [4, 5] among new and previ-
ously treated patients, respectively. However, most stud-
ies were conducted in urban areas and might not be
representative for rural remote regions of the country.
Besides, in Ethiopia, the socioeconomic, lifestyle and en-
vironmental conditions differ across regions, varying
from agricultural based to pastoral communities and
from semi-arid to humid fertile areas [7], and could
affect the distribution of drug-resistant M. tuberculosis
strains [8]. The current study was conducted among pa-
tients attending health facilities in the East Gojjam zone of
the Amhara region in northwest Ethiopia. East Gojjam
zone is one of the rural areas where the communities lead
their life mainly by farming and to date there is no report
on anti-tuberculosis drug resistance from this part of the
country. This study therefore determined the prevalence
of drug-resistant and MDR-TB among pulmonary TB pa-
tients attending two public hospitals in the region from
May 2011 to January 2012.
Methods
Study setting
This cross-sectional study was conducted in Debre Markos
Referral and Mota District hospitals located in the East
Gojjam zone of the Amhara region, northwest Ethiopia.
The prevalence of all forms of TB and smear-positive TB
in the Amhara Regional State was reported to be 643 and
168 per 100,000 populations, respectively [9]. East Gojjam
zone is divided into 18 administrative districts and agricul-
ture is the major source of income for more than 90 % of
its population. There are two public hospitals, more than
18 health centers, about 384 health posts, and 5 higher
and 25 medium private clinics providing service for about
3.5 million people in their catchment areas. In addition to
the two hospitals, all the 18 health centers provide sputum
smear microscopy and directly observed treatment short
course (DOTS) service. Moreover, the 5 higher and most
medium private clinics have currently implemented the
DOTS service [10, 11]. We conducted the current study at
the two public hospitals due to the fact that they represent
the largest center for TB diagnosis (referral sites for rural
communities) and considering feasibility.
Study population
From May 2011 to January 2012, a total of 385 pulmon-
ary TB suspected patients presenting at the two hospitals
were consecutively enrolled. Both smear-positive and
smear-negative patients were included. Inclusion criteria
were: age ≥ 15 years, willingness to participate in the
study (with informed consent including for HIV testing)
and clinical suspicion of pulmonary TB strong enough
to warrant a direct sputum smear for acid-fast bacilli
(AFB). Prior to sputum collection, data on demographic
information and history of previous treatment were col-
lected using a structured questionnaire. Then, three con-
secutive sputum samples (spot, morning and spot) were
collected from each patient. Direct microscopic examin-
ation of sputum for AFB after Ziehl- Neelsen staining
was performed at the laboratories of the respective hos-
pitals. Then samples were stored at 4 °C for a maximum
of 5 days until transported in a cold box to the Armauer
Hansen Research Institute (AHRI) in Addis Ababa for
culturing.
HIV testing
Testing for HIV was done according to the current Na-
tional algorithm recommended by the Federal Ministry
of Health of Ethiopia. Two rapid HIV tests, HIV (1 + 2)
Rapid Test Strip (KHB) and Stat-Pak were run sequen-
tially. Samples were tested first with KHB. Positive sam-
ples were confirmed with Stat-Pak. Discordant results
were resolved using a third confirmatory test kit, HIV-1/2
Unigold Recombinant assay. Pre and post-test HIV coun-
seling was provided for all consenting individuals.
Mycobacterial Culture
Sputum specimens were processed by the Petroff ’s method
following the standard operational procedures. In brief, an
equal volume of sputum specimen was mixed with an
equal volume of 4 % NaOH and concentrated at 3000 rpm
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for 15 min. The sediment was neutralized with 2 N HCL,
using phenol red as indicator, to prepare the inoculums for
culture. Then, three Lowenstein-Jensen slants, two con-
taining 0.75 % glycerol and one containing 0.6 % pyruvate,
were inoculated per each sputum sample. Culture tubes
were incubated at 37 °C and inspected for growth of
colonies weekly for up to 8 weeks. Mycobacteria were
confirmed with acid-fast bacilli (AFB) staining.
Region of difference 9 (RD9) deletion typing for
identification of M. tuberculosis
DNA was extracted by heat killing of the mycobacterial
colonies. Briefly, heat killed bacterial suspensions were
obtained by heating cultures suspended in Tris-EDTA
(TE) at 80 °C for one hour followed by incubation in an
ultrasonic bath for 5 min. Region of Difference analysis
was performed by using RD9 FlankFW, RD9 Int and
RDFlankRev primers as described previously [12]. Inter-
pretation of results was made on the basis of detection
of bands of different sizes [13]. For quality control, M.
tuberculosis H37Rv and M. bovis BCG (as positive con-
trol) and water (as a non-template control) were
included.
Conventional drug susceptibility testing
Drug susceptibility testing (DST) was performed by the
indirect proportion method on the enriched Middlebrook
7H10 agar media using a 24 well plate as recommended
by Bert van Klingeren et al. [14]. Stock solutions of each
drug were prepared using the appropriate solvent and the
following final drug concentrations (critical concentra-
tions) were used: isoniazid (INH), 0.2 μg/ml, rifampicin
(RIF),1.0 μg/ml, ethambutol (EMB), 5.0 μg/ml and
streptomycin (STM), 2.0 μg/ml as recommended else-
where [15]. Standardized bacterial suspension for each iso-
late was distributed in 10 μl volumes into 9 wells of the
24-well plate containing 7H10 medium with a precise
concentration of the selected anti-TB drugs and into the
10th well containing drug free medium. The 11th well of
each plate was inoculated with a mycobacterial solution
containing 1 % of the suspension (1:100 suspensions). This
was followed by incubation at 35 °C in the presence of suf-
ficient humidity and bacterial growth was checked on the
12th, 19th and 28th days. If the growth on drug containing
media with 1:1 bacterial suspensions was greater than the
growth on drug free control with 1:100 bacterial suspen-
sions, the isolate was defined as resistant and if it was
lower, the isolate was defined as susceptible to that par-
ticular drug. The test was repeated if the growth was equal
or nearly equal for both. For quality control, the reference
strain of M. tuberculosis H37Rv (ATCC 27294), which is
susceptible to the entire standard anti tuberculosis drugs,
was used in each batch of media prepared with drugs.
Resistance to a particular drug with or without resist-
ance to any of the other anti-TB drugs was denoted as
‘any resistance’. An MDR-TB patient was defined as one
whose sputum isolates showed resistance to isoniazid
and rifampicin with or without resistance to other anti-
TB drugs. Poly-resistance was defined as resistance to
more than one drug with the exception of the combin-
ation of isoniazid and rifampicin.
Data analysis
Data were entered using Epi Data entry version 3.1 soft-
ware and analyzed using SPSS version 21. Differences
between sputum culture positive and culture negative
groups were investigated using the x2 test (categorical
variables). Age was categorized into four levels. Bivariate
and multivariate logistic regression analysis was per-
formed to examine the association of independent vari-
ables with resistance outcome. Covariates with p-values
of ≤ 0.25 in the bivariate analysis were included in the
multivariate model. HIV status was considered as a po-
tential confounder and hence was assessed. Accordingly,
the multivariate model consisted of age (age group of
15–24 years as a referent), treatment category (new
cases as referent) and HIV status (HIV-negative patients
as a referent). Comparisons between subgroups (new
cases vs. retreatment cases, HIV-positive vs. HIV-
negative, and age groups) with resistance outcome were
expressed as odds ratios (OR) with a 95 % confidence
interval (CI). P-values of ≤ 0.05 were considered as statis-
tically significant.
Ethical issues
Ethical clearance was obtained from Aklilu Lemma Insti-
tute of Pathobiology, Addis Ababa University (AAU) and
AHRI/ALERT research ethics review committees. Writ-
ten informed consent was obtained from the study par-
ticipants and assent from parents/guardians for those
under 18 years of age. For illiterate participants, data
collectors informed each respondent and confirmed the
willingness of participants by signing on the informed
consent sheet. Moreover, confidentiality was assured for
all information provided. Confirmed MDR cases were
reported to the study hospitals for treatment.
Results
Characteristics of the study population
Of 385 pulmonary TB (PTB) suspects enrolled, 244
(63.4 %) were males and 141 (36.6 %) females with an
age range of 15 to 73 and mean age of 36.8 years. The
majority of the study participants, 326 (84.7 %), were
rural residents and more than three-fourths, 295
(76.6 %) were farmers. Illiterates numbered 267 (69.4 %)
and 118 (30.6 %) had completed primary school or
above. Ninety-two (23.9 %) of the study participants
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reported close contact with a TB patient and mostly
(89.0 %) at home. Eighty-nine (23.1 %) were HIV positive,
79 (20.5 %) were smear-positive, and 68 (17.7 %) had a
previous history of anti-TB therapy.
Culture result and relation to patient characteristics
Of 385 sputum samples, 124 (32.2 %) (from 82 male and
42 female patients) were culture positive. Eight (2.1 %)
were contaminated. Seventy-seven (97.5 %) of the
smear-positive and 47 (18.1 %) of the smear-negative
sputum samples were culture positive. Two (2.6 %)
smear-positive specimens were culture negative. Thirty-
four (36.9 %) of the 92 participants who reported close
contact with a TB patient were culture positive. Positive
cultures were more frequent among HIV-negative than
HIV-positive participants, but the difference was not sta-
tistically significant (P = 0.093). There was no significant
difference between the culture-positive and the culture-
negative groups in terms of HIV status, age distribution,
sex, and history of previous TB treatment (Table 1).
Region of difference (RD) based species typing
Region of difference based multiplex PCR for RD9 (RD9
analysis) showed that out of 124 isolates, 120 were M.
tuberculosis species. The remaining 4 isolates failed to
show any band on RD9 typing. No M. bovis was identi-
fied in this study.
Drug susceptibility patterns
Phenotypic drug susceptibility testing results were avail-
able for 89 (74 %) of the 120 isolates. However, the socio-
demographic and clinical characteristics of patients whose
isolates were not available for drug susceptibility testing
were not significantly different from those included except
that the loss was relatively higher in smear-negative
culture positive cases.
Resistance to at least one drug was detected in 18
(20.23 %, 95 % CI: 11.86-28.54) of the isolates of which
12 (20.7 %) were from males and 6 (19.4 %) from fe-
males. The highest proportions of any drug resistance
were observed in STM 7 (7.87 %, 95 % CI: 2.3-13.5)
followed by INH 6 (6.74 %, 95 % CI: 1.51-11.89) and
EMB 6 (6.74 %, 95 % CI: 1.51-11.89). Three isolates
(3.37 %, 95 % CI: 0.0-7.17) were MDR and 2 (2.24 %)
were poly resistant. One MDR isolate was resistant to all
the four anti-TB drugs tested. A summary of drug sus-
ceptibility pattern of the isolates is shown in Table 2.
Anti-TB drug resistance was more frequent among
retreatment patients than newly diagnosed cases (50.0 %
vs.15.58 %) and this difference was statistically significant
(crude OR = 5.42; 95 % CI: 1.49-19.64, P = 0.01). The
isolate which was resistant to the four anti-TB drugs
tested was also isolated from a previously treated patient.
The HIV prevalence among the study population for
whom drug resistance testing result available (n = 89)
was 19.1 % (17/89). The occurrence of drug resistance
was not related to HIV infection status (crude OR =
2.72; 95 % CI: 0.85- 8.88; P = 0.093), to positivity by mi-
croscopy of sputum smears (crude OR = 1.08; 95 % CI:
0.36-3.24; P = 0.88) or gender (crude OR = 1.52; 95 % CI:
0.48-4.69; P = 0.48). However, we found a significant as-
sociation between age and anti-TB drug resistance; those
in the group of 25–34 years were more likely to have
drug-resistant TB (crude OR = 4.67; 95 % CI: 1.25-17.44;
P = 0.022) as compared to patients in other age groups.
All the three MDR strains were also isolated from rural
HIV-seronegative patients in the age group of 25–34. After
fitting into the multivariate logistic regression model, age
(adjusted OR = 4.24; 95 % CI: 1.02-17.5; P = 0.046) and
Table 1 Baseline characteristics of participants enrolled in the study and their association with culture outcome as analyzed by the
x2 test
Characteristic Participants with positive sputum culture (n = 124), n (%) Participants with negative sputum culture (n = 261), n (%) P value*
Sex
Male 82 (66.1) 162 (62.0) 0.256
Female 42 (33.9) 99 (38.0)
HIV status
HIV-negative 102 (82.3) 67 (25.7) 0.093
HIV-positive 22 (17.7) 194 (74.3)
Previous history of treatment
No 107 (86.3) 51 (19.5) 0.198
Yes 17 (13.7) 210 (80.5)
Sputum microscopy
Smear-positive 77 (62.1) 2 (0.7) < 0.001
Smear-negative 47 (37.7) 259 (99.3)
*Comparing participants with a positive culture vs. participants with a negative culture. TB, Tuberculosis; HIV, Human Immunodeficiency Virus
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previous history of treatment (adjusted OR = 5.42; 95 % CI:
1.56-27.49; P = 0.01) remained independently associated
with occurrence of anti-TB drug resistance (Table 3).
Discussion
In this study, about a quarter of M.tuberculosis isolates
were resistant to at least one of the anti-TB drugs tested
(20.23 %). This is higher than a previous report in
Gondar (6.7 %) [16] but comparable to a resistance pro-
portion reported in Addis Ababa (22.3 %) [4]. However,
a relatively higher resistance proportion (60.8 %) has
been reported in another study from Addis Ababa [17].
The possible explanation for this difference could be due
to the fact that this study was conducted at St Peter’s TB
specialized hospital in Addis Ababa which is a referral site
for complicated TB cases from all parts of the country.
When compared to studies from other African countries,
our figure is also higher than a report from South Africa
(7.3 %) [18], but lower than a Kenyan study report
(30.1 %) [19].
The most frequent resistance proportion was observed
in STM (7.87 %). This drug has been in use since the be-
ginning of TB chemotherapy and hence a higher propor-
tion of STM resistance is expected. However, our figure
is lower than previous studies in Ethiopia which re-
ported 26.6 % [20] and 19.0 % [4] of STM resistance.
The relatively lower STM resistance in our study could
be attributed to time differences in that STM is no more
a first line drug (for most cases at least), since the
intensive phase was replaced with oral drugs which
could lead improved proportions of sensitive isolates
with time in recent years. The decreasing proportion of
STM resistance could be an advantage as the drug is in
the regimen for the treatment of TB patients in category
II and for other bacterial infections.
Resistance to INH in our study was 6.74 % which is
slightly higher than an earlier report in Addis Ababa
(5.5 %) [20] but lower than other reports in Ethiopia in
which 17 % [4] and 29.4 % [21] of the isolates were INH
resistant. Compared to recent studies in other regions of
Africa, our figure is comparable to a report in Rwanda
(6.2 %) [22], higher than from Uganda (3.2 %) [22, 23],
but lower than a finding in Kenya (12.9 %) [19]. Previous
studies conducted in 2002 and 2006 in Addis Ababa re-
ported that 4.1 % [5] and 2.3 % [17] of the isolates were
INH mono resistant in new cases and zero in previously
treated cases [5, 17]. In our study, INH mono-resistance
was detected only in 1 (1.1 %) of the isolates from a pre-
viously treated case.
The proportion of EMB resistance in this study (6.74 %)
is higher than previous findings in Ethiopia which ranged
from 0.0 % to 5.2 % [4, 24, 25]. Monoresistance to EMB
was also higher in new cases (5.19 %). This implies the ex-
istence of ongoing transmission of drug-resistant strains
in the study sites and could indicate weakness in TB pre-
vention and control measures as it is accompanied by
mono-resistance to RIF in new cases as well. Since EMB
enhances the effect of many other drugs including beta-
Table 2 Drug resistance patterns of M.tuberculosis strains isolated from newly diagnosed and previously treated pulmonary TB
patients attending two public hospitals in East Gojjam zone, northwest Ethiopia
Drug resistance pattern Isolates from new cases, n (%) Isolates from previously
treated cases, n (%)
Total, n (%) 95 % CI
77 (86.5) 12 (13.5) 89 (100.0)
Any resistance
Resistance to any drug 12 (15.58) 6 (50.0) 18 (20.23) 11.86-28.54
Any INH 2 (2.59) 4 (33.33) 6 (6.74) 1.51-11.89
Any RIF 3 (3.89) 2 (16.67) 5 (5.62) 0.82-10.38
Any EMB 4 (5.19) 2 (16.67) 6 (6.74) 1.51-11.89
Any STM 4 (5.19) 3 (25.0) 7 (7.87) 2.3-13.52
Mono resistance
INH alone 0 1 (8.3) 1 (1.12) 0.0-3.27
RIF alone 2 (2.59) 0 2 (2.24) 0.0-5.25
EMB alone 4 (5.19) 1 (8.33) 5 (5.62) 0.82-10.38
STM alone 3 (3.89) 0 3 (3.37) 0.0-7.14
Resistance to more than one drug
INH + RIF only (MDR) 1 (1.29) 1 (8.33) 2 (2.24) 0.0-5.25
INH + RIF + EMB + STM only 0 1 (8.33) 1 (1.12) 0.0-3.27
INH + STM only 0 2 (16.67) 2 (2.24) 0.0-5.25
CI, confidence interval; TB, tuberculosis; INH, isoniazid; STM, streptomycin; RIF, rifampicin; EMB, ethambutol
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lactam drugs on different mycobacterial species, the rise
of EMB resistance affects the advantage that could be
exploited to develop a regimen for the management of
MDR-TB [26].
Although the lowest proportion of resistance observed
in this study was in RIF (5.62 %), this is higher than previ-
ous reports in Ethiopia (0.1 % to 1.4 %) [5, 24, 25]. Mono-
resistance to RIF was observed in 2.59 % of the isolates
which is also higher than previous reports [5, 24]. The
relatively higher proportion of resistance to this drug in
this study might be attributed to the fact that RIF is largely
used in Ethiopia for the treatment of other bacterial infec-
tions. Since RIF is the most important drug to treat TB,
emergence of resistance to this drug has huge implications
for TB control policies. Even if the small sample size
might limit us to generalize, our findings suggest that the
precursors of MDR-TB are increasing in the study areas
as RIF resistance predicts MDR [26]. This could hamper
the effectiveness of the new RIF based six-month treat-
ment regimen adopted by the Federal Ministry of Health
of Ethiopia. Hence, proper use of this drug should be en-
sured in the study sites.
In this study, two factors were found to be associated
with anti-TB drug resistance; age group of 25–34 years
and having had a previous history of TB treatment. Several
studies documented the association between a previous
history of TB treatment and anti-TB drug resistance
[4, 25, 26]. With regard to age group, it is difficult to
directly compare with previous reports as different
studies used different cut-off points for age groups. A
study in South Africa, for instance, showed that age
groups of 35–54 and > 54 years were strongly associ-
ated with anti-TB drug resistance [27]. The association
observed in our study cloud be due to the high-risk
behavior of young people and hence a tendency to
interrupt TB treatment.
Multi drug resistance (MDR) was observed in 3 (3.37 %)
isolates in which 2 (16.67 %) were from previously treated
patients and one (1.29 %) from a newly diagnosed case.
Previous studies reported MDR proportions ranging from
0.6 % to 2.7 % [4, 17, 24, 28] and 3.5 % to 15.7 % [5, 21, 29]
among new and previously treated patients, respectively.
Our result of MDR-TB among newly diagnosed patients is
higher than a report in Addis Ababa (0.6 %), a study in
major towns of Amhara region (1.0 %) [24] and the WHO
estimate of 0.1 % primary MDR-TB in Ethiopia [1]. This
indicates that there is a progressive increase of MDR over
years imposing a serious public health threat. However, it
is also worthy to mention that the current magnitude of
anti-TB drug resistance in the study sites might have
changed since the isolates were collected nearly four years
ago. We recommend further large scale studies to be
conducted in the underlying population to quantify the
problem more precisely.
Although few studies have reported an association be-
tween HIV infection and development of drug resistance
Table 3 Bivariate and multivariate analysis for patient related risk factors for any drug resistance among pulmonary TB patients
attending two public hospitals in East Gojjam zone, northwest Ethiopia (n = 89)
Characteristic Any drug resistance COR (95 % CI) P-value AOR (95 % CI) p-value
Yes, n (%) No, n (%)
Sex
Male 13 (72.2) 45 (63.4) 1.52 (0.48-4.69) 0.48
Female 5 (27.8) 26 (36.6)
HIV-status
HIV-positive 6 (33.3) 11 (15.5) 2.72 (0.85-8.81) 0.093 2.76 (0.72-10.54) 0.14
HIV-negative 12 (66.7) 60 (84.5)
Age group (in years)
15-24 4 (22.2) 28 (39.4)
25-34 10 (55.6) 15 (21.1) 4.67 (1.25-17.44) 0.022 4.24 (1.02-17.5) 0.046
35-44 3 (16.6) 17 (23.9) 1.24 (0.25-6.21) 0.79 0.99 (0.18-5.65) 0.99
≥45 1 (5.6) 11 (15.6) 0.64 (0.064-6.35) 0.71 0.59 (0.05-6.36) 0.66
Previous history of treatment
Yes 6 (33.3) 6 (8.4) 5.42 (1.49-19.64) 0.01 6.55 (1.56-27.49) 0.01
No 12 (66.7) 65 (91.6)
Smear microscopy
Smear-positive 12 (66.7) 46 (64.8) 1.087 (0.36-3.24) 0.88
Smear-negative 6 (33.3) 25 (35.2)
AOR, Adjusted Odds Ratio; HIV, Human Immunodeficiency Virus; CI, Confidence Interval, COR, Crude Odds Ratio
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[30], our study did not find any association between HIV
infection status and anti-TB drug resistance. This lack of
association between HIV infection status and mycobac-
terial drug resistance is consistent with the results of
earlier studies in Addis Ababa [4, 5] and studies from
other sub-Saharan African countries [31, 32]. In our
study, the lack of association could be due to the low
number of known HIV positive cases included in the
study.
Our study was not without pitfalls. First, as the study
was conducted among TB patients seeking treatment
only at the two hospitals in the zone (health centers and
private clinics not included), data may not be representa-
tive of TB patients in the population of East Gojjam zone.
Moreover, the fact that our sample size was small might
have influenced our estimation of anti-TB drug resistance
proportion in the study sites. However, the current study
provides important data regarding drug resistance in rural
hospital settings and could be used by authorities in the
region to initiate appropriate interventions.
Conclusions
Overall, anti-TB drug resistance including MDR-TB is
comparable to previous studies in other parts of Ethiopian.
However, the relatively higher rate of RIF resistance ob-
served in our study signals the danger of increasing MDR-
TB in the study areas in the future. On the other hand, the
higher level of MDR-TB among previously treated patients
suggests the need to strengthen the DOTS strategy and the
capacity of laboratories to undertake DST especially among
previously treated patients.
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